Exhibit 107
Calculation of Filing Fee Table
Form S-8
(Form Type)
Revance Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| | | | | | | | | | | | | | | | | | | | | | | |
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
| Equity | 2014 Equity Incentive Plan Common Stock, par value $0.001 per share | Other (2) | 2,863,362 (3) | $12.32 (2) | $35,276,619.84 | $0.0000927 | $3,270.15 |
| Equity | 2014 Employee Stock Purchase Plan Common Stock, par value $0.001 per share | Other (4) | 300,000 (5) | $10.48 (4) | $3,144,000.00 | $0.0000927 | $291.45 |
Total Offering Amounts |
| $38,420,619.84 | | — |
| Total Fees Previously Paid | | | | — |
| Total Fee Offsets | | | | — |
| Net Fee Due | | | | $3,561.60 |
(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Common Stock of Revance Therapeutics, Inc. (the “Registrant”) that become issuable under the Registrant’s 2014 Equity Incentive Plan (the “2014 Plan”) and the Registrant’s 2014 Employee Stock Purchase Plan (the “2014 ESPP”) by reason of any stock dividend, stock split, recapitalization or other similar transaction.
(2)Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(h) and 457(c) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Market on February 24, 2022.
(3)Represents 2,863,362 additional shares of Common Stock available for issuance as a result of the annual evergreen increase on January 1, 2022 under the 2014 Plan.
(4)Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and 457(c) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Market on February 24, 2022, multiplied by 85%.
(5)Represents 300,000 additional shares of Common Stock available for issuance as a result of the annual evergreen increase on January 1, 2022 under the 2014 ESPP.
